Gilead Sciences raised its 2026 product-sales forecast on October 29 after reporting third-quarter growth in its HIV portfolio, while widening its projected annual adjusted loss.
The company now expects product sales of $31 billion to $31.3 billion, compared with $30.1 billion to $30.4 billion previously. It forecast an adjusted loss of 85 cents to $1.20 per share, versus a previous projected loss of 30–65 cents.
Gilead said annual earnings guidance includes approximately $12.4 billion in acquired research-and-development charges associated with transactions announced this year.
Third-quarter product sales rose 13% to $8.3 billion. HIV sales increased 18% to $6.2 billion, which Gilead attributed to higher realized prices, prevention demand and favorable inventory dynamics.
Biktarvy sales rose 10% to $4.1 billion. Meanwhile, cell-therapy product sales fell 18% to $355 million, reflecting competition, according to the company.
Quarterly GAAP diluted earnings fell to $1.94 per share from $2.43. Adjusted diluted earnings increased to $2.55 from $2.47. The annual guidance remains a forecast.
Sources: Gilead — October 29 Results: https://www.businesswire.com/news/home/20261029068948/en/Gilead-Sciences-Announces-Third-Quarter-2026-Financial-Results Dow Jones — Results and Outlook: https://www.marketscreener.com/news/gilead-sciences-lifts-sales-guidance-on-hiv-portfolio-strength-ce785fdadc88ff25